End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.85 EUR | -.--% | +1.19% | -58.33% |
May. 14 | Biophytis unveils design for obesity study | CF |
May. 14 | Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity | CI |
Sales 2024 * | - | Sales 2025 * | 4.8M 5.22M | Capitalization | 1.92M 2.08M |
---|---|---|---|---|---|
Net income 2024 * | -19M -20.65M | Net income 2025 * | -16M -17.39M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.4 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 40.58% |
1st Jan change | Capi. | |
---|---|---|
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+2.71% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- ALBPS Stock
- ALBPS Stock